Nanomedicine: Will It Get Big?
This article was originally published in Start Up
Executive Summary
Big drugmakers will be watching closely to see if second-generation nanomed companies can program small particles to pack big pharmaceutical effects. We profile four start-ups that hope to show that they can: Blend Biosciences, Kala Pharma, Qualiber Technologies, and Uroboros Technologies.
You may also be interested in...
U.K.’s Midatech Develops Transbuccal Insulin Using Gold Nanoparticles
The biocompatible gold nanoparticle technology being developed by the U.K. biotech can be used to carry insulin quickly to its site of action, and is also being evaluated with GLP-1 agonists and oncologics.
AstraZeneca Leaps Into Nanomedicine With Bind Cancer Deal
AstraZeneca signs on with Bind to develop a nanotechnology-based, targeted kinase inhibitor that could be used in a number of liquid and solid cancers. For Bind, the news is highly validating as the company’s third deal with a major biopharma in 2013.
Bind Lands Nanoparticle Development Deal With Pfizer
The nanoparticle biotech has signed an agreement with Pfizer to develop an undisclosed number of small molecules that will use the Accurins technology to make the particles easier to use in hard to treat diseases.